| Abstrakt: |
A recent study conducted at Zibo Municipal Hospital focused on the radiosensitivity of niraparib tosylate in treating esophageal squamous cell carcinoma (ESCC). The research found that niraparib tosylate, a poly ADP-ribose polymerase (PARP) inhibitor, enhanced the radiosensitivity of ESCC cells, leading to increased apoptosis and G2/M cycle arrest. The study also showed that the combination therapy of niraparib tosylate and radiotherapy was more effective under hypoxic and high-pressure conditions. These findings suggest a potential clinical application of niraparib tosylate in cancer therapy. [Extracted from the article] |
